Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394251
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Brief Title:
Study of Dose-dense Adriamycin Plus Cytoxan AC Followed by Either ABI-007 Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
An Open-label Randomized Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan AC Followed by Either ABI-007 Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study was to compare the safety of dose-dense ABI-007 Abraxane 260 mgm2 or Taxol 175 mgm2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan AC chemotherapy Bevacizumab was administered at 10 mgkg every 2 weeks throughout chemotherapy and then at 15 mgkg every 3 weeks following chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None